| Cat.No. | Name | Information |
|---|---|---|
| M2018 | GW4064 | GW4064 is a selective, non-steroidal agonist of the orphan nuclear receptor FXR with EC50 of 15 nM. |
| M6201 | Tropifexor | Tropifexor is a novel and highly potent agonist of farnesoid X receptor (FXR). |
| M2507 | Chenodeoxycholic acid | Chenodeoxycholic acid is an epimer of ursodeoxycholic acid, which inhibits the production of cholesterol in the liver and absorption in the intestines. |
| M42406 | XJ02862-S2 | XJ02862-S2 shows potent FXR agonistic activity. |
| M42405 | ZLY28 | ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. |
| M42404 | Hedragonic acid | Hedragonic acid is an oleane-type triterpenoid compound, which can be isolated from the stems and roots of the southern snake vine. |
| M40978 | FXR-314 | FXR-314 is an FXR agonist that can be used in studies related to non-alcoholic steatohepatitis (NASH). |
| M39141 | Nelumol A | Nelumol A is a farnesoid X receptor (FXR) agonist. |
| M39140 | Fargesone A | Fargesone A is a potent and selective FXR agonist. Fargesone A shows anti-inflammatory activity. |
| M31160 | HEC96719 | HEC96719 is a novel, selective, orally active tricyclic FXR agonist that activates FXR and induces expression of the target genes FGF15 and BSEP for nonalcoholic steatohepatitis (NASH) studies. |
| M22512 | EDP-305 | EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 can be used for the research of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). |
| M21185 | BMS-986318 | BMS-986318 is a potent non-bile acid FXR agonist with an EC50 of 53 and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has suitable ADME properties and is effective in a mouse model of hepatic cholestasis and fibrosis with bile duct ligation.BMS-986318 can be used in nonalcoholic steato BMS-986318 can be used in non-alcoholic steatohepatitis (NASH) studies. |
| M21058 | BMS-986339 | BMS-986339 is an oral farnesoid X receptor (FXR) agonist being developed for nonalcoholic steatohepatitis (NASH). |
| M8582 | NDB | NDB is a selective antagonist of human Farnesoid X receptor α (FXRα) that effectively modulates FXRα down-stream genes. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
